Laminin-111: A potential therapeutic agent for duchenne muscular dystrophy

Molecular Therapy

Volumn 18, Issue 12, 2010, Pages 2155-2163

  Goudenege, Sébastien ^a   Lamarre, Yann ^a   Dumont, Nicolas ^a   Rousseau, Joël ^a   Frenette, Jérôme ^a   Skuk, Daniel ^a   Tremblay, Jacques P ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; LAMININ; LAMININ 111; PHOSPHATE BUFFERED SALINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; ECCENTRIC MUSCLE CONTRACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MUSCLE ATROPHY; MUSCLE FORCE; MUSCLE REGENERATION; MUSCLE STRENGTH; MYOBLAST; MYOSITIS; NONHUMAN; RAT; TREATMENT OUTCOME;

MUS;

EID: 78650919007     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.165     Document Type: Article

References (46)

1. Hoffman, E P, Brown, RH Jr and Kunkel, LM (1987). Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
2. Ervasti, JM and Campbell, KP (1993). Dystrophin-associated glycoproteins: their possible roles in the pathogenesis of Duchenne muscular dystrophy. Mol Cell Biol Hum Dis Ser 3: 139-166.
3. Durbeej, M (2010). Laminins. Cell Tissue Res 339: 259-268.
4. Campbell, KP (1995). Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80: 675-679.
5. Porter, JD, Khanna, S, Kaminski, HJ, Rao, JS, Merriam, AP, Richmonds, CR et al. (2002). A chronic infammatory response dominates the skeletal muscle molecular signature in dystrophin-defcient mdx mice. Hum Mol Genet 11: 263-272.
6. Kinoshita, I, Vilquin, JT and Tremblay, JP (1996). Mechanism of increasing dystrophin-positive myofbers by myoblast transplantation: study using mdx/beta-galactosidase transgenic mice. Acta Neuropathol 91: 489-493.
7. Skuk, D and Tremblay, JP (2000). Progress in myoblast transplantation: a potential treatment of dystrophies. Microsc Res Tech 48: 213-222.
8. Skuk, D, Paradis, M, Goulet, M, Chapdelaine, P, Rothstein, DM and Tremblay, JP (2010). Intramuscular transplantation of human postnatal myoblasts generates functional donor-derived satellite cells. Mol Ther (epub ahead of print).
9. Skuk, D, Goulet, M, Roy, B, Chapdelaine, P, Bouchard, JP, Roy, R et al. (2006). Dystrophin expression in muscles of Duchenne muscular dystrophy patients after high-density injections of normal myogenic cells. J Neuropathol Exp Neurol 65: 371-386.
10. Silva-Barbosa, SD, Butler-Browne, GS, de Mello, W, Riederer, I, Di Santo, JP, Savino, W et al. (2008). Human myoblast engraftment is improved in laminin-enriched microenvironment. Transplantation 85: 566-575.
11. Rooney, JE, Gurpur, PB and Burkin, DJ (2009). Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc Natl Acad Sci USA 106: 7991-7996.
12. Rooney, JE, Gurpur, PB, Yablonka-Reuveni, Z and Burkin, DJ (2009). Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy. Am J Pathol 174: 256-264.
13. Skuk, D and Tremblay, JP (2003). Myoblast transplantation: the current status of a potential therapeutic tool for myopathies. J Muscle Res Cell Motil 24: 285-300.
14. Hoffman, E P, Monaco, AP, Feener, CC and Kunkel, LM (1987). Conservation of the Duchenne muscular dystrophy gene in mice and humans. Science 238: 347-350.
15. Morgan, JE, Hoffman, EP and Partridge, TA (1990). Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. J Cell Biol 111 (6 Pt 1): 2437-2449.
16. Carnwath, JW and Shotton, DM (1987). Muscular dystrophy in the mdx mouse: histopathology of the soleus and extensor digitorum longus muscles. J Neurol Sci 80: 39-54.
17. Coulton, GR, Curtin, NA, Morgan, JE and Partridge, TA (1988). The mdx mouse skeletal muscle myopathy: II. Contractile properties. Neuropathol Appl Neurobiol 14: 299-314.
18. Coulton, GR, Morgan, JE, Partridge, TA and Sloper, JC (1988). The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol 14: 53-70.
19. Melo, F, Carey, DJ and Brandan, E (1996). Extracellular matrix is required for skeletal muscle differentiation but not myogenin expression. J Cell Biochem 62: 227-239.
20. Osses, N and Brandan, E (2002). ECM is required for skeletal muscle differentiation independently of muscle regulatory factor expression. Am J Physiol, Cell Physiol 282: C383-C394.
21. Bajanca, F, Luz, M, Raymond, K, Martins, GG, Sonnenberg, A, Tajbakhsh, S et al. (2006). Integrin alpha6beta1-laminin interactions regulate early myotome formation in the mouse embryo. Development 133: 1635-1644.
22. Burkin, DJ and Kaufman, SJ (1999). The alpha7beta1 integrin in muscle development and disease. Cell Tissue Res 296: 183-190.
23. Kroll, TG, Peters, BP, Hustad, CM, Jones, PA, Killen, PD and Ruddon, RW (1994). Expression of laminin chains during myogenic differentiation. J Biol Chem 269: 9270-9277.
24. Kühl, U, Timpl, R and von der Mark, K (1982). Synthesis of type IV collagen and laminin in cultures of skeletal muscle cells and their assembly on the surface of myotubes. Dev Biol 93: 344-354.
25. Vachon, PH, Loechel, F, Xu, H, Wewer, UM and Engvall, E (1996). Merosin and laminin in myogenesis; specifc requirement for merosin in myotube stability and survival. J Cell Biol 134: 1483-1497.
26. von der Mark, K and Ocalan, M (1989). Antagonistic effects of laminin and fbronectin on the expression of the myogenic phenotype. Differentiation 40: 150-157.
27. Skuk, D, Goulet, M, Roy, B and Tremblay, JP (2000). Myoblast transplantation in whole muscle of nonhuman primates. J Neuropathol Exp Neurol 59: 197-206.
28. Skuk, D, Goulet, M, Roy, B and Tremblay, JP (2002). Effcacy of myoblast transplantation in nonhuman primates following simple intramuscular cell injections: toward defning strategies applicable to humans. Exp Neurol 175: 112-126.
29. Kariya, Y and Miyazaki, K (2004). The basement membrane protein laminin-5 acts as a soluble cell motility factor. Exp Cell Res 297: 508-520.
30. Kikkawa, Y, Takahashi, N, Matsuda, Y, Miwa, T, Akizuki, T, Kataoka, A et al. (2009). The infuence of synthetic peptides derived from the laminin alpha1 chain on hepatocyte adhesion and gene expression. Biomaterials 30: 6888-6895.
31. Malinda, KM, Wysocki, AB, Koblinski, JE, Kleinman, HK and Ponce, ML (2008). Angiogenic laminin-derived peptides stimulate wound healing. Int J Biochem Cell Biol 40: 2771-2780.
32. Vande Broek, I, Vanderkerken, K, De Greef, C, Asosingh, K, Straetmans, N, Van Camp, B et al. (2001). Laminin-1-induced migration of multiple myeloma cells involves the high-affnity 67 kD laminin receptor. Br J Cancer 85: 1387-1395.
33. Hoberg, M, Rudert, M, Pap, T, Klein, G, Gay, S and Aicher, WK (2007). Attachment to laminin-111 facilitates transforming growth factor beta-induced expression of matrix metalloproteinase-3 in synovial fbroblasts. Ann Rheum Dis 66: 446-451.
34. Warstat, K, Hoberg, M, Rudert, M, Tsui, S, Pap, T, Angres, B et al. (2009). TGF-{beta}1 and laminin-111 cooperate in the induction of IL-16 expression in synovial fbroblasts from rheumatoid arthritis patients. Ann Rheum Dis (epub ahead of print).
35. Egeblad, M and Werb, Z (2002). New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174.
36. Birkedal-Hansen, H (1993). Role of matrix metalloproteinases in human periodontal diseases. J Periodontol 64 (5 suppl.): 474-484.
37. Birkedal-Hansen, H, Moore, WG, Bodden, MK, Windsor, LJ, Birkedal-Hansen, B, DeCarlo, A et al. (1993). Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4: 197-250.
38. Werle, MJ (2008). Cell-to-cell signaling at the neuromuscular junction: the dynamic role of the extracellular matrix. Ann N Y Acad Sci 1132: 13-18.
39. Nishimura, T, Nakamura, K, Kishioka, Y, Kato-Mori, Y, Wakamatsu, J and Hattori, A (2008). Inhibition of matrix metalloproteinases suppresses the migration of skeletal muscle cells. J Muscle Res Cell Motil 29: 37-44.
40. Bouchentouf, M, Benabdallah, BF, Rousseau, J, Schwartz, LM and Tremblay, JP (2007). Induction of Anoikis following myoblast transplantation into SCID mouse muscles requires the Bit1 and FADD pathways. Am J Transplant 7: 1491-1505.
41. Mueller, GM, O'Day, T, Watchko, JF and Ontell, M (2002). Effect of injecting primary myoblasts versus putative muscle-derived stem cells on mass and force generation in mdx mice. Hum Gene Ther 13: 1081-1090.
42. Rousseau, J, Dumont, N, Lebel, C, Quenneville, SP, Côté, CH, Frenette, J et al. (2010). Dystrophin expression following the transplantation of normal muscle precursor cells protects mdx muscle from contraction-induced damage. Cell Transplant (epub ahead of print).
43. Liu, M, Yue, Y, Harper, SQ, Grange, RW, Chamberlain, JS and Duan, D (2005). Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 11: 245-256.
44. Warren, GL, Lowe, DA and Armstrong, RB (1999). Measurement tools used in the study of eccentric contraction-induced injury. Sports Med 27: 43-59.
45. Huard, J, Tremblay, G, Verreault, S, Labrecque, C and Tremblay, JP (1993). Utilization of an antibody specifc for human dystrophin to follow myoblast transplantation in nude mice. Cell Transplant 2: 113-118.
46. Rando, TA and Blau, HM (1994). Primary mouse myoblast purifcation, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 125: 1275-1287.